CATX EBITDA Growth
Perspective Therapeutics Inc · EBITDA Growth
CATX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-21.06%period ending
CATX TTM EBITDA YoY % (100.00% → -21.06%)
Year-over-year change
High-resolution chart · PNG
CATX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -21.0582% | |
| -28.1478% | |
| -30.2676% | |
| -136.1781% | |
| -130.5384% | |
| -125.4936% | |
| -95.0602% | |
| -30.7082% | |
| -49.4274% | |
| -90.0904% | |
| -281.8913% | |
| -277.9334% | |
| -286.2803% | |
| -227.3525% | |
| -87.61% | |
| -88.6808% | |
| -118.3736% | |
| -82.3111% | |
| -76.29% | |
| -49.673% | |
| 1.7423% | |
| -1.7179% | |
| 20.4482% | |
| 29.9214% | |
| 36.8311% | |
| 48.8279% | |
| 40.1778% | |
| 30.9003% | |
| 21.096% | |
| -5.004% | |
| -6.6003% | |
| -6.7966% | |
| -6.6762% | |
| -11.2386% | |
| -54.0524% | |
| -152.8988% | |
| -755.1737% | |
| -703.6325% | |
| -141.0713% | |
| 6.5251% | |
| 80.1157% | |
| 81.5299% | |
| 54.3512% | |
| 29.8923% | |
| 5.2461% | |
| -4.745% | |
| -6.8538% | |
| -7.9958% | |
| -12.4175% | |
| -13.7432% | |
| -5.4836% | |
| -12.6063% | |
| -18.3452% | |
| -17.1861% | |
| -46.8258% | |
| -17.929% | |
| -23.2002% | |
| 7.1735% | |
| 35.34% | |
| 13.0293% | |
| 21.2905% | |
| 8.5867% | |
| 1.4306% | |
| 39.8583% | |
| 45.6083% | |
| 43.7604% | |
| 43.1712% | |
| 23.2067% | |
| 25.8468% | |
| 37.377% | |
| 33.2035% | |
| 22.1999% | |
| 16.8815% | |
| 0.2387% | |
| -12.4807% | |
| -10.2637% | |
| -38.1068% | |
| -131.0832% | |
| -203.2857% | |
| -408.0966% | |
| -1,829.1249% | |
| -2,309.5415% | |
| -121,802.2876% | |
| 5,066.998% | |
| 4,248.2618% | |
| 100% | |
| 100% | |
| 100% | |
| 100% |